Our laboratory is interested to study the function of ILCs, which are the innate counterpart of T cells. ILCs are present at the mucosal site where they quickly initiate cytokine response against pathogens. In 2019, in a seminal study published in Nature, we along with the Leslie Lab, AHRI, showed that an IL-17/IL-22 producing ILC subset, namely ILC3s, play a crucial role in early innate immune response to TB. We identified CXCR5 mediated mechanism of ILC3 accumulation within the iBALT structure of TB granuloma (Ardain et al. 2019). We also investigated the role of transcription factor, aryl hydrocarbon receptor (ahr) in ILC3 development in collaboration with the laboratory of Dr. Marco Colonna. We are investigating the transcriptome and epigenome of ILCs modified during TBs (also in vaccine model). We are also interested in studying the ILC plasticity in the murine model of tuberculosis.